A quality team sees a demo of a large language model answering questions about a batch record and asks the only question that matters in a regulated plant: how do we validate this? The honest answer is not “you can’t.” AI in a GxP environment is a computerized system, and computerized systems have been validated in pharma for decades. The mistake is treating every model as bespoke, high-risk software when a risk-based approach — the one your organization already uses for other systems — applies here too.
Why AI in a GxP environment worries quality teams
The fear is reasonable. AI feels different from the LIMS or MES a validation lead already knows: the model is probabilistic, its logic is opaque, and a generative system can produce a confident, well-written answer that is simply wrong. Under 21 CFR Part 11 and EU GMP Annex 11, records and decisions that affect product quality must be attributable, accurate and traceable — and a black box that occasionally invents facts is a hard thing to sign off.
But “hard to trust by default” is a design problem, not a dead end. The reframe that unlocks the whole topic is this: you are not validating “AI” in the abstract — you are validating a specific system, for a specific intended use, at a level of rigor that matches its risk. A model that drafts an internal literature summary a scientist then checks is not the same risk as a model that releases a batch. Treating them identically — either banning both or over-validating both — is what stalls programs.
The GAMP 5 approach, extended for AI
GAMP 5 (Good Automated Manufacturing Practice) is the established framework for computerized system validation, and its second edition already leans on Computer Software Assurance (CSA) — a critical-thinking, risk-based mindset that puts effort where patient and product risk actually is, rather than generating documentation for its own sake. In July 2025 ISPE published the GAMP 5 AI Guide, which extends that same thinking to AI and machine learning instead of inventing a parallel regime.
The shape of AI validation under this approach is recognizable:
- Intended use first. Define precisely what the system does, what decisions it informs, and where its output goes. Risk flows from intended use — the same model is low-risk for internal drafting and high-risk for a quality decision.
- Risk assessment. Assess the impact on patient safety, product quality and data integrity. High-risk uses get more rigor; low-risk uses get proportionate, lighter controls.
- Data and model lifecycle control. This is the genuinely new part. Control the data that trains, tunes or grounds the model, version the model, and manage change — a retrained model or a swapped foundation model is a change to be assessed, not a silent update.
- Human oversight. Keep a qualified person accountable for the outcome, especially for anything touching a GxP decision. Human-in-the-loop is a control, not a courtesy.
- Ongoing monitoring. A model can drift as inputs shift. Unlike a fixed calculation, it needs monitoring in production — accuracy, drift, and out-of-scope questions — not a one-time qualification and done.
- IQ/OQ/PQ where risk warrants. Installation, Operational and Performance Qualification still apply — scaled to risk. Test that the system is installed correctly, operates as specified, and performs against real, representative cases.
The result is defensible because it is proportionate: you can show an inspector exactly why a given control exists and why the level of testing matches the risk.
Making generative AI and RAG compliant: governed RAG
Free-running generative AI is the part that rightly makes quality teams nervous — a model answering from its own training data can hallucinate. The pattern that makes generative AI defensible in a regulated setting is governed, validated RAG (Retrieval-Augmented Generation).
Instead of letting the model answer from memory, governed RAG retrieves passages from a controlled set of validated sources — approved SOPs, validated batch records, current specifications — and constrains the model to answer from those passages. This grounding is what suppresses hallucination: the answer is built from retrieved, source-of-truth text, not invented, and every claim can be traced back to where it came from.
Grounding is the difference between an AI that sounds authoritative and one you can defend to an inspector. If every sentence points back to a validated source, the system is answering from your records — not from its imagination.
Layer the standard controls on top and the mapping to 21 CFR Part 11 and EU GMP Annex 11 becomes concrete:
- Full citations. Every answer cites the exact source document and section, so a reviewer can verify it rather than trust it.
- Human-in-the-loop. A qualified reviewer approves output before it drives a GxP action — the accountable human the regulation expects.
- Audit trails. Who asked what, what the system retrieved, what it answered and who approved it — captured immutably, supporting ALCOA+ data-integrity expectations.
- Access control. The system only retrieves from sources a user is authorized to see, and only authorized users can act on its output.
Built this way, a RAG assistant is not an ungovernable black box. It is a computerized system with a controlled knowledge base, deterministic retrieval, human sign-off and a complete record — the things an Annex 11 or Part 11 assessment asks for.
From pilot to validated production: escaping “pilot purgatory”
Most AI in pharma never reaches production. A promising pilot demos well, then stalls — a state common enough to have a name: pilot purgatory. The cause is rarely the model. It is that the pilot was never built to be validated, monitored or integrated in the first place.
A demo optimized to impress a steering committee skips exactly the things production requires: it grounds on a stale copy of documents instead of the live controlled source, it has no audit trail, no access control, no monitoring, and no validation package. Turning that into a GxP system is not a finishing step — it is a rebuild. So the project dies in the gap between “it worked in the demo” and “we can release it in a regulated plant.”
The fix is to design for validated production from day one, even in the pilot:
- Write the intended use and risk assessment before building. Know what will need validating so the pilot is a small version of the real system, not a throwaway.
- Ground on the real, controlled sources. Point the pilot at the validated source-of-truth from the start, so the trust model doesn't change on the way to production.
- Instrument audit trail and monitoring early. Capture retrieval, answers, approvals and accuracy from the first day — retrofitting them later means rework.
- Integrate, don't island. A system that lives beside the workflow instead of inside it never survives contact with production.
The substrate: a FAIR data foundation
Governed RAG is only as trustworthy as what it retrieves from. If the underlying data is scattered across systems, poorly labeled or contradictory, no amount of prompting saves the answer. This is why validated AI in life sciences rests on a FAIR data foundation — data that is Findable, Accessible, Interoperable and Reusable — often organized as a knowledge graph that captures how processes, materials, equipment and records relate.
That substrate is what lets a system retrieve the right validated source and present a defensible, connected answer instead of a plausible guess. Get the data foundation right and the AI on top becomes both more accurate and far easier to validate. Skip it, and every model you deploy inherits the ambiguity underneath.
The takeaway
AI in a GxP environment is not a special exemption from validation, and it is not un-validatable either. It is a computerized system that you assess for intended use and risk, control across its data and model lifecycle, keep a human accountable for, and monitor in production — exactly the risk-based discipline GAMP 5 and the ISPE GAMP 5 AI Guide describe. Make it generative through governed, validated RAG, and grounding, citations, human-in-the-loop and audit trails turn “we can’t trust it” into a system you can defend against 21 CFR Part 11 and EU GMP Annex 11.
The teams that succeed do not run a clever pilot and then wonder how to validate it. They design for validated production from the first day, on a FAIR data foundation built to be retrieved from. That is the work A4BEE does — building production-grade, validated AI for regulated life sciences on a governed data substrate. See our Enterprise AI capability for how the pieces fit together.